Lung Cancer Clinical Trial
Lung EpiCheck Biomarkers Development Study
Summary
This study is part of the development of a non-invasive lung cancer screening test which aim to identify early-stage lung cancer in patients at high risk for lung cancer.
Full Description
This is a prospective, multi-center, observational nonsignificant risk study aimed to collect blood and clinical data from primary lung cancer and control subjects to characterize various biomarkers that will discriminate between lung cancer and control subjects.
Eligibility Criteria
Inclusion Criteria - Cases:
Age 50-80 years
Subjects who are currently smoking or former smokers, with at least 20 pack-years
Subjects with either A high suspicion for lung cancer, with planned biopsy or surgery to establish a definitive diagnosis within 60 days after enrollment or treatment naive lung cancer patients confirmed by pathology.
Exclusion Criteria - Cases
Known diagnosis or treatment of cancer from any kind in the past 5 years, except of fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix and except from the current lung cancer
Inclusion Criteria - USPSTF risk
Age 50-80 years
Subjects who are currently smoking or former smokers, with at least 20 pack-years
Exclusion Criteria - USPSTF risk
- Known diagnosis or treatment of cancer of any kind in the past 5 years, except for fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix
Inclusion Criteria - Healthy controls
Age 20-80 years
Never smoker or current / previous smoker < 20 pack year history
Exclusion Criteria - Healthy Controls
Known diagnosis or treatment of cancer of any kind in the past (lifetime), except for fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix.
Not previously diagnosed with a lung lesion highly suspicious for cancer
Under follow up or work up for any lesion suspicious for any type of cancer
Presenting with fever with body temperature 100.4°F (38°C) or higher
Acute exacerbation or flare of an inflammatory condition requiring escalation in medical therapy within 14 days prior to blood draw
Pregnancy
Any history of blood product transfusion within 30 days prior to blood draw
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 6 Locations for this study
Miami Florida, 33130, United States
Panama City Florida, 32405, United States
Shreveport Louisiana, 71106, United States
Southfield Michigan, 48076, United States
Troy Michigan, 48084, United States
San Antonio Texas, 78229, United States
Budapest , , Hungary
Haifa , , Israel
Tel Aviv , , Israel
Hengelo , , Netherlands
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.